Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Protagonist Therapeutics to related companies based on the strength of its earnings, risk, profitability, institutional ownership, dividends, valuation and analyst recommendations.
Volatility & Risk
Protagonist Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics’ peers have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.
Valuation and Earnings
This table compares Protagonist Therapeutics and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Protagonist Therapeutics | $46.02 million | -$130.15 million | 28.57 |
| Protagonist Therapeutics Competitors | $750.19 million | $13.49 million | -19.24 |
Protagonist Therapeutics’ peers have higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Protagonist Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protagonist Therapeutics | 0 | 0 | 16 | 1 | 3.06 |
| Protagonist Therapeutics Competitors | 9869 | 15280 | 45598 | 1598 | 2.54 |
Protagonist Therapeutics presently has a consensus target price of $166.67, suggesting a potential upside of 23.58%. As a group, “Biotechnology” companies have a potential upside of 121.32%. Given Protagonist Therapeutics’ peers higher probable upside, analysts plainly believe Protagonist Therapeutics has less favorable growth aspects than its peers.
Profitability
This table compares Protagonist Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protagonist Therapeutics | 62.04% | 42.83% | 40.29% |
| Protagonist Therapeutics Competitors | -12,323.33% | -195.38% | -30.39% |
Insider & Institutional Ownership
98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Protagonist Therapeutics beats its peers on 9 of the 13 factors compared.
About Protagonist Therapeutics
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
